Chromatography Resins for Biologics Patents: Who Leads, Gaps 2026
- Two assignees hold every record in scope. The ranked leader and one other company together account for 100% of the 12 records, leaving no independent third filer in this specific search.
- Filing activity peaked in 2019, then went flat. From a high of 7 records in 2019, filings fell to zero by 2022 and have stayed there through the most recent partial year.
- Analytical and formulation claims are barely touched. G01N and A61K each appear in just 8.3% of records, leaving resin-plus-analytics and resin-plus-formulation claims largely open.
A narrow, concentrated claim space
Chromatography resin patents for biologics cover the materials and ligand chemistries used to purify recombinant proteins, antibodies, and antibody-drug conjugates during downstream bioprocessing. This search returns 12 records spanning 2015 through the 2026 cut-off, concentrated on mixed mode and ion-exchange ligand chemistries evaluated against dynamic binding capacity, cleaning and lifetime cycles, and host-cell-protein clearance.
The field here is small enough that two ranked assignees account for the entire set of records, and filing activity has not recovered since a 2019 peak. That combination — high concentration, flat recent activity — makes this a good candidate for a targeted freedom-to-operate check rather than a broad competitive scan.
Filing trend and technology composition
The 12 records in scope span 2015 through the 2026 cut-off, with filing activity concentrated around a single peak year and a technology mix weighted toward resin chemistry and separation processes.
Filing activity peaked in 2019 and has not recovered
Filings ran from zero in 2017 to a peak of 7 in 2019, then fell back to zero at the 2022 midpoint and remain at zero through the most recent partial year. Because publication lags filing by roughly 18 months, the last one to two years understate true activity, but the multi-year flat stretch before that is a real signal, not an artefact of the lag.
Resin chemistry and separation processes dominate the classification mix
B01J (chemical and physical processes, 66.7% of the 12 records) and B01D (separation processes, 58.3%) are the two largest classes, each co-occurring frequently with C07K (peptides and proteins, 58.3%). A61K and G01N each appear in only 8.3% of records, marking the analytical and formulation adjacencies as thin by comparison. Because a single record can carry multiple IPC classes, these shares sum to more than 100% of the record total and should not be added together.
Shares are the percentage of the 12 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Chromatography Resins for Biologics with Eureka
This page is one run against one query. Ask Eureka your own question about chromatography resins for biologics and every answer comes back with the patent numbers behind it.
Try EurekaThe claims setting the boundary in this field
Anionic exchange-hydrophobic mixed mode chromatography resin
Chromatography resins having anionic exchange-hydrophobic mixed mode ligands, useful for purifying target biomolecules using anionic exchange and hydrophobic mixed mode chromatography together. The resins allow efficient purification of recombinant proteins, antibodies, antibody-drug conjugates, and antibody derivatives including fragments and fusions, and have been found useful in purifying monomeric target biomolecules from aggregate target biomolecules — a common polishing step in antibody manufacturing.Filed by Bio-Rad Laboratories; family member WO2019173731A1 is the most-cited record in this dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2019173731A1 | Anionic exchange-hydrophobic mixed mode chromatography resin | 14 |
| 2 | US20200406232A1 | Anionic exchange-hydrophobic mixed mode chromatography resin | 4 |
| 3 | CN111818980A | 阴离子交换-疏水混合模式色谱树脂 | 3 |
Ranked by citation count within the 12 records returned by this search; older records accumulate citations by nature of being searchable longer, so treat this as a signal of influence rather than current importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Publication numbers are shown where the record carries one (3 of 3 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the filing pattern signals
With only 12 records and two ranked assignees, this is a narrow, concentrated claim space rather than a sprawling one — the signal is in what is claimed densely versus what is barely touched at all.
No independent third filer in scope
The top 2 combined and top 5 combined figures are identical at 100.0% of all 12 records, because the ranking itself contains only two assignees. Any competitive or freedom-to-operate assessment in this claim space begins and ends with those two.
Activity has not recovered since 2019
Filings dropped to zero by the 2022 midpoint and stayed at zero through the latest partial year. Some of the most recent gap reflects publication lag, but the multi-year flat stretch predates that window.
Resin chemistry claims dominate
B01J and B01D together cover the bulk of records, both frequently paired with C07K peptide and protein claims. This points to resin material claims bundled with a purification process claim rather than filed as standalone chemistry.
Analytics and formulation are thin
Only one record each touches material analysis/testing (G01N) or medicinal preparation claims (A61K). That leaves resin-to-analytics and resin-to-formulation combination claims comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to chromatography resins for biologics, with the prior art for and against each one.
Who holds the claims
Only two assignees appear in the ranking for this search, and together they account for every record in scope — a sign of a narrow, tightly claimed niche rather than a broad multi-player field.
Concentration at the top
The leading assignee holds 8 of the 12 records in this search, the largest single share by a wide margin given there are only two ranked assignees total.
Recent filings have gone quiet
The leading assignee shows zero filings in the latest year, a -100% year-on-year change. Publication lag means some of this is provisional, but it follows a multi-year flat stretch that predates the lag window.
No long tail in this search
Unlike broader technology searches with dozens of filers, this claim space returns just two ranked assignees covering all 12 records, leaving no independent third-party filer to benchmark against within scope.
| Assignee | Recent year | YoY |
|---|---|---|
| Bio-Rad Laboratories, Inc. | 0 | -100% |
| Kochurus Oncology Ltd. | 0 | — |
Where to go from this landscape
This search returns a narrow set of 12 records concentrated on mixed-mode and ion-exchange resin chemistry. The next useful step depends on whether you need freedom-to-operate certainty or want to explore the adjacent white space.
Run a claim chart on the leading family
With two assignees holding all 12 records, a detailed claim chart against the leading family's mixed-mode ligand claims is the fastest way to confirm freedom to operate before committing to a resin chemistry.
Build a claim chart in EurekaTest the analytics and formulation adjacencies
G01N and A61K each cover only 8.3% of records, leaving resin-plus-analytics and resin-plus-formulation combination claims open. A targeted novelty search on those combinations can confirm whether a first claim is genuinely available.
Search white space in EurekaCommon questions on chromatography resin patents
In this dataset, two ranked assignees together account for all 12 records in scope, with one clearly leading at 8 records. That is a small, concentrated field rather than a broad competitive landscape, so any freedom-to-operate check should start with that leader's family before looking elsewhere. Because this is a narrow search string rather than a full-field survey, treat this as evidence about mixed-mode and ion-exchange resin claims specifically, not about chromatography resins in general.
Mixed mode resins combine two separation mechanisms, typically ion exchange and hydrophobic interaction, in a single ligand, which lets a purification step separate biomolecules by both charge and hydrophobicity at once. In this dataset the most-cited records apply this specifically to separating monomeric antibodies from aggregate species, a common polishing step for antibody and antibody-drug conjugate manufacturing. The appeal for manufacturers is fewer process steps for equivalent purity, which is why the claim language in the leading family centres on aggregate clearance rather than the resin chemistry alone.
The filing trend in this dataset peaked at 7 records in 2019 and fell to zero by the 2022 midpoint, staying flat through the most recent partial year. Publication lag of roughly 18 months means the most recent one to two years are always undercounted, so some of that drop-off is an artefact of records not yet being published. But the multi-year flat stretch before the cut-off is longer than the lag alone would explain, suggesting filing activity in this specific claim space genuinely slowed rather than merely being delayed in publication.
US20200406232A1, assigned to Bio-Rad Laboratories, claims chromatography resins with anionic exchange-hydrophobic mixed mode ligands for purifying target biomolecules including recombinant proteins, antibodies, antibody-drug conjugates, and antibody fragments or fusions. Its practical significance is the specific application to separating monomeric target biomolecules from aggregate forms, which is a purification step many antibody manufacturing processes rely on. Its family member, WO2019173731A1, carries a higher citation count, indicating this claim language is a reference point other filers in this space have needed to work around.
The IPC composition points to two thin adjacencies: G01N (material analysis and testing) and A61K (medicinal preparations), each present in only 8.3% of the 12 records. That means resin performance claims exist, but claims tying a specific resin chemistry to an in-line analytical verification step, or to a formulated drug product, are largely unclaimed in this dataset. A first claim combining a mixed-mode or ion-exchange resin's dynamic binding capacity with an in-process analytical detection method would sit outside the current concentration of claims.
Research Chromatography Resins for Biologics in depth with Eureka
Go past this page: query the whole chromatography resins for biologics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.